VW Transporter Turns 70 As The Longest-Surviving Commercial Vehicle

putri titian

When you think about vehicles that have stood out the test of time, the first on your list would probably the Chevrolet Suburban, which entered production in 1935 and currently the longest-surviving vehicle nameplate in the world. The Ford F-Series trucks will also be a likely candidate, dating back to […]

When you think about vehicles that have stood out the test of time, the first on your list would probably the Chevrolet Suburban, which entered production in 1935 and currently the longest-surviving vehicle nameplate in the world. The Ford F-Series trucks will also be a likely candidate, dating back to 1948 when the first of the F-Series pickup family first appeared.

The VW Beetle could have been also part of the list, dating back to 1949 – if only the German marque didn’t decide to ax the name recently. However, there’s another VW that have stood the test of time, and it’s the Transporter.

With 13 million units sold worldwide, the VW Transporter is officially celebrating its 70th birthday and currently stands as the longest-running commercial vehicle nameplate. Now on its sixth generation, the very first Transporter rolled off the Wolfsburg production line on March 8, 1950. It was also known as the Bulli, Kombi, VW bus, or microbus. Let’s take a little trip down the memory lane.

The T1 started out as a hand-built panel van in 1949, which then evolved into a rear-engined panel van, passenger van, and eight-seat bus. Its first examples are powered by the same engine found in the Beetle, with a maximum payload capacity of 1,653 pounds (750 kilograms). By 1967, around 1.9 million units of the Transporter T1 have been sold.

Fast forward to today, the VW Transporter T6.1 has been revealed in 2019. Now with a new engine, intelligent driver assistance systems, infotainment, and a redesigned front-end, the T6.1 gets a two-tone paint scheme as a nod to the original T1.

Source Article

Next Post

Bicycle Therapeutics partners with Roche

Bicycle Therapeutics, a Cambridge, UK-based biotech, developing proprietary bicyclic peptides has attracted the attention of Roche subsidiary, Genentech. The two companies agreed a collaboration agreement, with Bicycle receiving $30m (€27.4m) in an upfront fee and eligible for a further $1.7bn (€1.55bn) dependent upon milestones met. The focus will be on […]